Development of Clopidogrel Polymeric Nanoparticles with Sustained Release and Improved Bioavailability for the Treatment of Myocardial Infarction | Synapse
March 3, 2026
Development of Clopidogrel Polymeric Nanoparticles with Sustained Release and Improved Bioavailability for the Treatment of Myocardial Infarction
Key Points
Improved bioavailability of clopidogrel increases therapeutic efficacy in myocardial infarction, suggesting better outcomes.
Bioavailability improved by 30% with polymeric nanoparticles, enhancing drug delivery and efficacy.
Development of clopidogrel polymeric nanoparticles features sustained release for prolonged therapeutic effect.
Potential for clinical application is significant, warranting further investigation for safety and effectiveness.